凋亡相關(guān)因子配體(FASL)活性蛋白
Active Factor Related Apoptosis Ligand (FASL)
CD178; CD95L; CD95-L; FASLG; FASLG; APT1LG1; APT1-LG1; TNFSF6; Fas Antigen Ligand; TNF Superfamily Member 6; Tumor Necrosis Factor(ligand)Superfamily,Member 6
- 編號(hào)APA031Hu01
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 80%
- 等電點(diǎn)9.2
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 1152 ¥ 2880 ¥ 5760 ¥ 17280 ¥ 43200
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
活性實(shí)驗(yàn)
Fas ligand (FasL) is a 40?kDa type?II membrane protein belonging to the TNF family. In the new TNF super family nomenclature, FasL is referred to as TNFSF6. The specific receptor for FasL is Fas (CD95,?Apo-1), a 45?kDa type?I transmembrane protein that is a member of the TNF receptor family. FasL is predominantly expressed on activated T?cells and NK?cells, while Fas is expressed on various types of cells. The Fas/FasL system plays a crucial role in modulating immune response by inducing cell apoptosis to maintain homeostasis, self-tolerance of lymphocytes, and immune privilege. FasL was reported to be a potent chemoattractant for neutrophils, suggesting a novel proinflammatory function of this molecule. A functional ELISA assay was conducted to detect the interaction of recombinant human FASL and recombinant human FAS. Briefly, FASL was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to FAS-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-FASL pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μL stop solution to the wells and read at 450/630nm immediately. The binding activity of recombinant human FASL and recombinant human FAS was shown in Figure 1, the EC50?for this effect is 0.044 ug/mL.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過(guò)一個(gè)月,-80°C不超過(guò)12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA031Hu01 | 凋亡相關(guān)因子配體(FASL)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA031Hu02 | 凋亡相關(guān)因子配體(FASL)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APA031Hu01 | 凋亡相關(guān)因子配體(FASL)活性蛋白 | Cell?culture;?Activity?Assays. |
PAA031Hu02 | 凋亡相關(guān)因子配體(FASL)多克隆抗體 | WB; IHC; ICC; IP. |
PAA031Hu01 | 凋亡相關(guān)因子配體(FASL)多克隆抗體 | WB; IHC; ICC; IP. |
FAA031Hu01 | 抗凋亡相關(guān)因子配體(FASL)多克隆抗體 | Flow cytometry. |
LAA031Hu71 | 凋亡相關(guān)因子配體(FASL)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
MAA031Hu22 | 凋亡相關(guān)因子配體(FASL)單克隆抗體 | WB; IHC; ICC; IP. |
SEA031Hu | 凋亡相關(guān)因子配體(FASL)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA031Hu | 凋亡相關(guān)因子配體(FASL)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
KSA031Hu01 | 凋亡相關(guān)因子配體(FASL)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
PLoS Pathogens | Macrophage-expressed IFN-β Contributes to Apoptotic Alveolar Epithelial Cell Injury in Severe Influenza Virus Pneumonia [PubMed: PMC3585175] |
Tumor Biology | The diplotype Fas? 1377A/? 670G as a genetic marker to predict a lower risk of breast cancer in Chinese women [Springer:Source] |
IOS Press Content Library | An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer's … [articles:journal-of-alzheimers-disease] |
博士論文 | INSTITUTO DE CIENCIAS BáSICAS Y PRECLíNICAS “VICTORIA DE GIRóN” DEPARTAMENTO DE HISTOLOGíA [] |